Genome-wide identification of genes essential for the survival of Streptococcus pneumoniae in human saliva

PLoS One. 2014 Feb 25;9(2):e89541. doi: 10.1371/journal.pone.0089541. eCollection 2014.

Abstract

Since Streptococcus pneumoniae transmits through droplet spread, this respiratory tract pathogen may be able to survive in saliva. Here, we show that saliva supports survival of clinically relevant S. pneumoniae strains for more than 24 h in a capsule-independent manner. Moreover, saliva induced growth of S. pneumoniae in growth-permissive conditions, suggesting that S. pneumoniae is well adapted for uptake of nutrients from this bodily fluid. By using Tn-seq, a method for genome-wide negative selection screening, we identified 147 genes potentially required for growth and survival of S. pneumoniae in saliva, among which genes predicted to be involved in cell envelope biosynthesis, cell transport, amino acid metabolism, and stress response predominated. The Tn-seq findings were validated by testing a panel of directed gene deletion mutants for their ability to survive in saliva under two testing conditions: at room temperature without CO2, representing transmission, and at 37 °C with CO2, representing in-host carriage. These validation experiments confirmed that the plsX gene and the amiACDEF and aroDEBC operons, involved in respectively fatty acid metabolism, oligopeptide transport, and biosynthesis of aromatic amino acids play an important role in the growth and survival of S. pneumoniae in saliva at 37 °C. In conclusion, this study shows that S. pneumoniae is well-adapted for growth and survival in human saliva and provides a genome-wide list of genes potentially involved in adaptation. This notion supports earlier evidence that S. pneumoniae can use human saliva as a vector for transmission.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bacterial Proteins / genetics*
  • Gene Expression Regulation, Bacterial
  • Genome, Bacterial / genetics*
  • Humans
  • Pneumococcal Infections / genetics*
  • Pneumococcal Infections / microbiology
  • Pneumococcal Infections / mortality*
  • Saliva / microbiology*
  • Streptococcus pneumoniae / genetics
  • Streptococcus pneumoniae / growth & development*
  • Streptococcus pneumoniae / pathogenicity
  • Survival Rate

Substances

  • Bacterial Proteins

Grants and funding

This work was financially supported by Nano Cluster of Technology Foundation STW FES0901: FES HTSM, European Community's Seventh Framework Programme FP7/2007-2013 under grant agreement number HEALTH-F3-2009-222983 (Pneumopath project), and Agentschap NL project number OM111009 (Pneumovac project). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.